Browsing Schizophrenia and Psychotic Disorders by Title
Now showing items 59-78 of 126
-
Identifying individuals at risk of developing psychosis: A systematic review of the literature in primary care services
(2023-01)Psychosis and related disorders are a major public health issue. Early identification and prevention for those at high risk (at-risk-mental-state, ARMS) is important. General practitioners (GPs) are often the first point ... -
‘If he feels better I'll feel better’ relationships with individuals at high-risk of developing psychosis
(2021-03)A large proportion of individuals with an at-risk mental state (ARMS) live at home and are supported by their families. Recommended treatment includes family intervention (FI), and therefore, understanding relationships ... -
The impact of Patient and Public Involvement in the SlowMo study: Reflections on peer innovation
(2021-09)Background: The SlowMo study demonstrated the effects of SlowMo, an eight-session digitally supported reasoning intervention, on paranoia in a large-scale randomized-controlled trial with 362 participants with schizophre ... -
In Vivo Availability of Cannabinoid 1 Receptor Levels in Patients With First-Episode Psychosis
(2019-07)Importance: Experimental and epidemiological studies implicate the cannabinoid 1 receptor (CB1R) in the pathophysiology of psychosis. However, whether CB1R levels are altered in the early stages of psychosis and whether ... -
Intravenous immunoglobulin and rituximab versus placebo treatment of antibody-associated psychosis: study protocol of a randomised phase IIa double-blinded placebo-controlled trial (SINAPPS2)
(2019-06)Background: Evidence is conflicting about a causal role of inflammation in psychosis and, specifically, regarding antibodies binding to neuronal membrane targets, especially N-methyl-D-aspartate receptors. NMDAR, LGI1 and ... -
Is adjunctive CBT really effective for schizophrenia?
(2019-09)Although antipsychotic medication remains the mainstay of treatment for schizophrenia, medications alone are not always successful. Cognitive– behavioural therapy (CBT) is recommended as an adjunct to pharmacological ... -
Is modafinil an effective adjunct to standard care in the treatment of schizophrenia-spectrum disorders?
(2022-08)Antipsychotics are the cornerstone of schizophrenia management but they are not adequate in treating the negative and cognitive symptoms of the illness. The Cochrane review discussed in this commentary examines the safety ... -
Is there a choice to make? A pilot study investigating attitudes towards treatment in an Early Intervention for Psychosis service
(2018-03)Purpose The purpose of this paper is to investigate health care professionals’ (HCPs) and service-users’ (SUs) attitudes towards different treatment options in an Early Intervention for Psychosis (EIP) service as well as ... -
The journey of adolescent paranoia: A qualitative study with patients attending child and adolescent mental health services
(2022-02)Objectives: Paranoia is most likely to emerge in adolescence. In adolescents with mental health disorders, the disruptive effect of paranoia on social relationships could worsen outcomes. However, little is known about ... -
Kalirin as a Novel Treatment Target for Cognitive Dysfunction in Schizophrenia
(2021-12)The cognitive dysfunction experienced by patients with schizophrenia represents a major unmet clinical need. We believe that enhancing synaptic function and plasticity by targeting kalirin may provide a novel means to ... -
Ketamine for Psychiatric Disorders
(2019-07)This new edition of The ECT Handbook comes six years after the publication of the 3rd edition. In the intervening period there have been no major changes in the practice of electroconvulsive therapy, but continuing research ... -
A life more ordinary: A peer research method qualitative study of the Feeling Safe Programme for persecutory delusions
(2022-07)Background: The Feeling Safe Programme is a cognitive therapy developed to improve outcomes for individuals with persecutory delusions. It is theoretically driven, modular and personalised, with differences in ... -
Measuring dissociation across adolescence and adulthood: Developing the short-form Cernis Felt Sense of Anomaly scale (CEFSA-14)
(2023-05)Dissociation may be important across many mental health disorders, but has been variously conceptualised and measured. We introduced a conceptualisation of a common type of dissociative experience, ‘felt sense of anomaly’ ... -
Measuring Disturbance of the Endocannabinoid System in Psychosis A Systematic Review and Meta-analysis
(2019-06)Importance: The endocannabinoid system (ECS) is a lipid-based endogenous signaling system. Its relevance to psychosis is through the association between cannabis use and the onset and course of illness and through the ... -
Measuring reasoning in paranoia: Development of the Fast and Slow Thinking Questionnaire
(2020-07)Paranoid thoughts are common across the psychosis continuum. It is well established that reasoning biases (conceived as an overreliance on fast thinking and lack of willingness and/or ability to engage in slow thinking) ... -
Mental health professionals’ experiences of working with parents with psychosis and their families: a qualitative study
(2021-04)Healthcare service users who are parents with psychosis form part of the caseload of most community mental health teams. Mental health professionals can experience uncertainty about how to work with and ask about the ... -
Mindfulness and acceptance based therapies for psychosis.
(2021-06)This chapter describes two approaches—person-based cognitive therapy (PBCT) and acceptance and commitment therapy (ACT)—that belong to the group of "third-wave" or contextual cognitive-behavioral therapies (CBTs). "Thirdwave" ... -
The Needs and Experiences of Parents with Psychosis: A Qualitative Interview Study
(2022-09)Over a third of individuals diagnosed with a psychotic disorder are also a parent. The symptoms of psychosis and side effects of antipsychotic medication can impact on parents’ awareness of the needs of their children and, ... -
Neuroimaging glutamatergic mechanisms differentiating antipsychotic treatment-response
(2023-06)Glutamatergic dysfunction is associated with failure to respond to antipsychotic medication in individuals with schizophrenia. Our objective was to combine neurochemical and functional brain imaging methods to investigate ... -
New drug targets in psychiatry: Neurobiological considerations in the genomics era
(2022-07)After a period of withdrawal, pharmaceutical companies have begun to reinvest in neuropsychiatric disorders, due to improvements in our understanding of these disorders, stimulated in part by genomic studies. However, ...